Oncolytics Biotech Stock Price Prediction
| ONC Stock | CAD 1.33 0.04 2.92% |
Oversold Vs Overbought
43
Oversold | Overbought |
EPS Estimate Next Quarter (0.11) | EPS Estimate Current Year (0.45) | EPS Estimate Next Year (0.47) | Wall Street Target Price 6.75 | EPS Estimate Current Quarter (0.10) |
Using Oncolytics Biotech hype-based prediction, you can estimate the value of Oncolytics Biotech from the perspective of Oncolytics Biotech response to recently generated media hype and the effects of current headlines on its competitors.
The fear of missing out, i.e., FOMO, can cause potential investors in Oncolytics Biotech to buy its stock at a price that has no basis in reality. In that case, they are not buying Oncolytics because the equity is a good investment, but because they need to do something to avoid the feeling of missing out. On the other hand, investors will often sell stocks at prices well below their value during bear markets because they need to stop feeling the pain of losing money.
Oncolytics Biotech after-hype prediction price | CAD 1.39 |
There is no one specific way to measure market sentiment using hype analysis or a similar predictive technique. This prediction method should be used in combination with more fundamental and traditional techniques such as stock price forecasting, technical analysis, analysts consensus, earnings estimates, and various momentum models.
Oncolytics |
Oncolytics Biotech After-Hype Price Prediction Density Analysis
As far as predicting the price of Oncolytics Biotech at your current risk attitude, this probability distribution graph shows the chance that the prediction will fall between or within a specific range. We use this chart to confirm that your returns on investing in Oncolytics Biotech or, for that matter, your successful expectations of its future price, cannot be replicated consistently. Please note, a large amount of money has been lost over the years by many investors who confused the symmetrical distributions of Stock prices, such as prices of Oncolytics Biotech, with the unreliable approximations that try to describe financial returns.
Next price density |
| Expected price to next headline |
Oncolytics Biotech Estimiated After-Hype Price Volatility
In the context of predicting Oncolytics Biotech's stock value on the day after the next significant headline, we show statistically significant boundaries of downside and upside scenarios based on Oncolytics Biotech's historical news coverage. Oncolytics Biotech's after-hype downside and upside margins for the prediction period are 0.07 and 6.64, respectively. We have considered Oncolytics Biotech's daily market price in relation to the headlines to evaluate this method's predictive performance. Remember, however, there is no scientific proof or empirical evidence that news-based prediction models outperform traditional linear, nonlinear models or artificial intelligence models to provide accurate predictions consistently.
Current Value
Oncolytics Biotech is extremely dangerous at this time. Analysis and calculation of next after-hype price of Oncolytics Biotech is based on 3 months time horizon.
Oncolytics Biotech Stock Price Prediction Analysis
Have you ever been surprised when a price of a Company such as Oncolytics Biotech is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Oncolytics Biotech backward and forwards among themselves. Have you ever observed a lot of a particular company's price movement is driven by press releases or news about the company that has nothing to do with actual earnings? Usually, hype to individual companies acts as price momentum. If not enough favorable publicity is forthcoming, the Stock price eventually runs out of speed. So, the rule of thumb here is that as long as this news hype has nothing to do with immediate earnings, you should pay more attention to it. If you see this tendency with Oncolytics Biotech, there might be something going there, and it might present an excellent short sale opportunity.
| Expected Return | Period Volatility | Hype Elasticity | Related Elasticity | News Density | Related Density | Expected Hype |
0.15 | 5.25 | 0.06 | 0.01 | 2 Events / Month | 1 Events / Month | In a few days |
| Latest traded price | Expected after-news price | Potential return on next major news | Average after-hype volatility | ||
1.33 | 1.39 | 4.51 |
|
Oncolytics Biotech Hype Timeline
Oncolytics Biotech is now traded for 1.33on Toronto Exchange of Canada. The entity has historical hype elasticity of 0.06, and average elasticity to hype of competition of 0.01. Oncolytics is forecasted to increase in value after the next headline, with the price projected to jump to 1.39 or above. The average volatility of media hype impact on the company the price is over 100%. The price boost on the next news is estimated to be 4.51%, whereas the daily expected return is now at 0.15%. The volatility of related hype on Oncolytics Biotech is about 10988.37%, with the expected price after the next announcement by competition of 1.34. Oncolytics Biotech has accumulated about 11.67 M in cash with (28.45 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.72. Assuming the 90 days trading horizon the next forecasted press release will be in a few days. Check out Oncolytics Biotech Basic Forecasting Models to cross-verify your projections.Oncolytics Biotech Related Hype Analysis
Having access to credible news sources related to Oncolytics Biotech's direct competition is more important than ever and may enhance your ability to predict Oncolytics Biotech's future price movements. Getting to know how Oncolytics Biotech's peers react to changing market sentiment, related social signals, and mainstream news is a great way to find investing opportunities and time the market. The summary table below summarizes the essential lagging indicators that can help you analyze how Oncolytics Biotech may potentially react to the hype associated with one of its peers.
| HypeElasticity | NewsDensity | SemiDeviation | InformationRatio | PotentialUpside | ValueAt Risk | MaximumDrawdown | |||
| APS | Aptose Biosciences | 0.03 | 2 per month | 0.00 | (0.23) | 5.66 | (10.53) | 34.00 | |
| RVX | Resverlogix Corp | 0.25 | 6 per month | 0.00 | (0.04) | 16.67 | (14.29) | 34.29 | |
| XHB | iShares Canadian HYBrid | 0.01 | 3 per month | 0.13 | (0.48) | 0.41 | (0.31) | 1.07 | |
| ALA-PA | Altagas Cum Red | 0.00 | 0 per month | 0.67 | (0.18) | 1.15 | (1.45) | 3.73 | |
| ERE-UN | European Residential Real | 0.02 | 2 per month | 0.72 | 0.16 | 3.95 | (1.48) | 20.23 | |
| CLU | iShares Fundamental Hedged | 0.00 | 0 per month | 0.35 | (0.03) | 1.07 | (0.97) | 4.36 | |
| RUDB | RBC Discount Bond | 0.05 | 1 per month | 0.34 | (0.28) | 0.58 | (0.62) | 1.96 | |
| BN-PFI | Brookfield | 0.15 | 5 per month | 0.00 | (0.23) | 1.09 | (1.12) | 2.87 | |
| XEG | iShares SPTSX Capped | (0.08) | 1 per month | 1.64 | (0.05) | 2.20 | (2.34) | 8.20 |
Oncolytics Biotech Additional Predictive Modules
Most predictive techniques to examine Oncolytics price help traders to determine how to time the market. We provide a combination of tools to recognize potential entry and exit points for Oncolytics using various technical indicators. When you analyze Oncolytics charts, please remember that the event formation may indicate an entry point for a short seller, and look at other indicators across different periods to confirm that a breakdown or reversion is likely to occur.| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
About Oncolytics Biotech Predictive Indicators
The successful prediction of Oncolytics Biotech stock price could yield a significant profit to investors. But is it possible? The efficient-market hypothesis suggests that all published stock prices of traded companies, such as Oncolytics Biotech, already reflect all publicly available information. This academic statement is a fundamental principle of many financial and investing theories used today. However, the typical investor usually disagrees with a 'textbook' version of this hypothesis and continually tries to find mispriced stocks to increase returns. We use internally-developed statistical techniques to arrive at the intrinsic value of Oncolytics Biotech based on analysis of Oncolytics Biotech hews, social hype, general headline patterns, and widely used predictive technical indicators.
We also calculate exposure to Oncolytics Biotech's market risk, different technical and fundamental indicators, relevant financial multiples and ratios, and then comparing them to Oncolytics Biotech's related companies. | 2023 | 2024 (projected) | Net Debt To EBITDA | 1.02 | 1.52 | Intangibles To Total Assets | 0.0149 | 0.0141 |
Story Coverage note for Oncolytics Biotech
The number of cover stories for Oncolytics Biotech depends on current market conditions and Oncolytics Biotech's risk-adjusted performance over time. The coverage that generates the most noise at a given time depends on the prevailing investment theme that Oncolytics Biotech is classified under. However, while its typical story may have numerous social followers, the rapid visibility can also attract short-sellers, who usually are skeptical about Oncolytics Biotech's long-term prospects. So, having above-average coverage will typically attract above-average short interest, leading to significant price volatility.
Other Macroaxis Stories
Our audience includes start-ups and big corporations as well as marketing, public relation firms, and advertising agencies, including technology and finance journalists. Our platform and its news and story outlet are popular among finance students, amateur traders, self-guided investors, entrepreneurs, retirees and baby boomers, academic researchers, financial advisers, as well as professional money managers - a very diverse and influential demographic landscape united by one goal - build optimal investment portfolios
Story Categories
Currently Trending Categories
Oncolytics Biotech Short Properties
Oncolytics Biotech's future price predictability will typically decrease when Oncolytics Biotech's long traders begin to feel the short-sellers pressure to drive the price lower. The predictive aspect of Oncolytics Biotech often depends not only on the future outlook of the potential Oncolytics Biotech's investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Oncolytics Biotech's indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 67.6 M | |
| Cash And Short Term Investments | 34.9 M |
Check out Oncolytics Biotech Basic Forecasting Models to cross-verify your projections. To learn how to invest in Oncolytics Stock, please use our How to Invest in Oncolytics Biotech guide.You can also try the Portfolio Backtesting module to avoid under-diversification and over-optimization by backtesting your portfolios.